Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Bio-Path Holdings ( (BPTH) ) has provided an announcement.
Bio-Path Holdings has announced successful preclinical testing of BP1001-A, showing enhanced insulin sensitivity, indicating its potential as a treatment for obesity and Type 2 diabetes. The studies confirmed BP1001-A’s ability to downregulate Grb2 expression, enhance metabolic events, and increase insulin sensitivity, offering a promising alternative to current treatments as the company plans further development and animal studies in anticipation of human trials.
More about Bio-Path Holdings
Bio-Path Holdings, Inc. is a biotechnology company that utilizes its proprietary DNAbilize® liposomal delivery and antisense technology to develop targeted nucleic acid cancer drugs. The company is focused on creating RNAi nanoparticle drugs for cancer treatment, with its lead product candidates, prexigebersen (BP1001) undergoing a Phase 2 study for blood cancers and BP1001-A in a Phase 1/1b study for solid tumors.
YTD Price Performance: -92.78%
Average Trading Volume: 1,201,095
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.88M
For detailed information about BPTH stock, go to TipRanks’ Stock Analysis page.
